NASDAQ: IMCRImmunocore Holdings PLC Stock
$30.10-0.37 (-1.21%)
Updated Apr 30, 2025
IMCR Price
$30.10
Fair Value Price
N/A
Market Cap
$1.51B
52 Week Low
$23.15
52 Week High
$62.74
P/E
-29.51x
P/B
4.18x
P/S
4.75x
PEG
N/A
Dividend Yield
N/A
Revenue
$310.20M
Earnings
-$51.09M
Gross Margin
99.1%
Operating Margin
-10.99%
Profit Margin
-16.5%
Debt to Equity
1.8
Operating Cash Flow
$26M
Beta
0.74
Next Earnings
May 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A
IMCR Overview
Immunocore Holdings plc develops immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. It offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Other oncology programs include IMC-C103C, in Phase I/II dose escalation trials in patients with solid tumor cancers (non-small-cell lung, gastric, head and neck, ovarian, and synovial sarcoma cancers), and IMC-F106C, in Phase I/II dose escalation trials in patients with multiple solid tumor cancers (non-small-cell lung, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers). Immunocore was founded in 1999 and is headquartered in Abingdon, UK.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine IMCR's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
IMCR
Ranked#161 of 462
Ranked#161 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.07 | A | |
| $8.24 | A | |
| $24.29 | A |
Be the first to know about important IMCR news, forecast changes, insider trades & much more!
IMCR News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how IMCR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IMCR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
IMCR is good value based on its book value relative to its share price (4.18x), compared to the US Biotechnology industry average (4.45x)
P/B vs Industry Valuation
IMCR is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more IMCR due diligence checks available for Premium users.
Valuation
IMCR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-29.51x
Industry
-162.28x
Market
29.18x
IMCR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.18x
Industry
4.45x
IMCR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
IMCR's financial health
Profit margin
Revenue
$84.1M
Net Income
-$23.8M
Profit Margin
-28.3%
IMCR's Earnings (EBIT) of -$34.09M... subscribe to Premium to read more.
Interest Coverage Financials
IMCR's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.0B
Liabilities
$648.8M
Debt to equity
1.8
IMCR's short-term assets ($929.86M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IMCR's short-term assets ($929.86M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IMCR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
IMCR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$14.0M
Investing
-$3.5M
Financing
-$51.5M
IMCR's operating cash flow ($26.06M)... subscribe to Premium to read more.
Debt Coverage Financials
IMCR vs Biotech Stocks
Immunocore Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.